|
|
|
|
|
|
Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Career Definitions
Labor Market Reports
Education & Training
Regions
Market Summary
News
IPOs
Company Profiles
Companies
Events
BioPharm Insight
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
Mixed Outlook for Pharmaceutical Industry following Healthcare Reform, Datamonitor (DTM.L) Reports
3/24/2010
Tijana Ignjatovic, strategic healthcare analyst at Datamonitor, believes that the House of Representatives passing the biggest reform of healthcare in the country for 40 years is a double-edged sword for the pharmaceutical industry.
The industry will be grateful for some certainty on the future market outlook and, overall, there is a strong belief that the pharmaceutical industry will benefit from the reform.
However, while many factors will determine the financial impact of proposed US healthcare reform on the branded pharmaceutical industry, Datamonitor believes that there are potential short and long-term dangers.
In the short term, it is likely that imposed discounts and rebates, in addition to raised industry fees will lead to a market dip. This couldn’t come at a worse time for an industry facing patent expiries in 2011 that are set to wipe tens of billions of dollars off annual revenue.
However, from 2015 onwards, these negative effects will be offset as revenues begin to rise, driven mainly by the increase in the number of insured people and the resulting increase in drug consumption.
While this will be beneficial in the medium-term, greater government participation in provision of healthcare will inevitably ensue. In addition, growing cost strain on both public and private payers will lead to increased negative pressures on the pharmaceutical industry in the US, decreasing the overall value growth of the market. It cannot be ruled out that unfavorable measures such as drug re-importation and Medicare Part D price negotiations may be introduced as healthcare costs start to bite.
Generic providers will also be questioning the benefits of the reform, despite a highly favorable outlook at the beginning of the process and President Obama’s pro-generics stance. Although the promise of higher sales volume from more insured patients and growing cost-containment pressures will be seen as a great positive, the 12 years exclusivity given to branded biologics, which is substantially longer than the usual 5 years given to small molecule drugs, will be a concern.
With the introduction of a ban on refusal of insurance coverage for pre-existing conditions and removal of annual or lifetime coverage limits, the health insurance industry will be hit hard by reform, with its profitability in jeopardy despite the increase in the number of customers.
|
|
|
|
|
|
|
|
|
|
|
|